# Cell–Cell Interactome-Based Pathogenesis and Therapies for Osteosarcoma

**Authors:** Sriya Neelam, Abdulaziz Hakeem, Yang Yang, Shuying Yang

PMC · DOI: 10.3390/cells15060570 · 2026-03-23

## TL;DR

This review explains how interactions between osteosarcoma cells and their surrounding environment drive cancer progression and resistance to treatment, suggesting new therapeutic strategies.

## Contribution

The paper provides a comprehensive synthesis of tumor-microenvironment interactions in osteosarcoma and identifies novel therapeutic strategies based on these mechanisms.

## Key findings

- Tumor-microenvironment interactions involving endothelial cells, fibroblasts, and immune cells drive osteosarcoma progression and therapy resistance.
- Exosome communication, immune evasion, and vascular remodeling are key mechanisms contributing to osteosarcoma aggressiveness.
- Targeting these interactions could improve treatment outcomes through precision medicine and microenvironment-focused therapies.

## Abstract

What are the main findings?
The review systematically summarizes how tumor–microenvironment interactions, involving endothelial cells, fibroblasts, stromal cells, immune populations, and osteoclasts, drive osteosarcoma metastasis, therapy resistance, and tumor progression.Key molecular and cellular mechanisms, including exosome communication, signaling pathway activation, immune evasion, and vascular remodeling, are identified as central contributors to osteosarcoma aggressiveness.

The review systematically summarizes how tumor–microenvironment interactions, involving endothelial cells, fibroblasts, stromal cells, immune populations, and osteoclasts, drive osteosarcoma metastasis, therapy resistance, and tumor progression.

Key molecular and cellular mechanisms, including exosome communication, signaling pathway activation, immune evasion, and vascular remodeling, are identified as central contributors to osteosarcoma aggressiveness.

What are the implications of the main findings?
Understanding these cellular crosstalk mechanisms provides a foundation for developing targeted therapies, immunomodulatory strategies, and microenvironment-focused interventions to overcome therapy resistance and metastatic spread.The integrated insights from this review support precision medicine approaches, highlight actionable molecular targets, and guide future research to improve the clinical management of osteosarcoma.

Understanding these cellular crosstalk mechanisms provides a foundation for developing targeted therapies, immunomodulatory strategies, and microenvironment-focused interventions to overcome therapy resistance and metastatic spread.

The integrated insights from this review support precision medicine approaches, highlight actionable molecular targets, and guide future research to improve the clinical management of osteosarcoma.

Osteosarcoma (OS), the most common primary malignant bone tumor in children and young adults, is characterized by aggressive behavior, frequent metastasis, and resistance to chemotherapy, resulting in poor clinical outcomes. Increasing evidence indicates that OS progression is not solely driven by tumor-intrinsic factors but is strongly influenced by dynamic interactions within the tumor microenvironment (TME). This literature review synthesizes current research on the roles of endothelial cells, fibroblasts, mesenchymal stromal cells, immune populations, and osteoclasts in OS pathogenesis, with emphasis on cell–cell interactions mediated by direct contact, soluble factors, and extracellular vesicles. The studies demonstrate that these interactions promote tumor proliferation, immune evasion, extracellular matrix remodeling, metastatic dissemination, and therapeutic resistance. Adaptive responses of both tumor and stromal cells to environmental stressors contribute to chemoresistance and disease progression. Collectively, our findings highlight the multifactorial nature of OS driven by complex cellular crosstalk within the TME. Understanding these mechanisms highlights the limitations of conventional chemotherapy and encourages the development of combined therapeutic approaches, including targeted therapies, immunomodulation, and microenvironmental interventions. Continued investigation into tumor–microenvironment interactions may facilitate the identification of actionable targets and improve personalized treatment approaches for OS.

## Linked entities

- **Diseases:** osteosarcoma (MONDO:0002623)

## Full-text entities

- **Genes:** SELE (selectin E) [NCBI Gene 6401] {aka CD62E, ELAM, ELAM1, ESEL, LECAM2, selectin-e}, CXADRP1 (CXADR pseudogene 1) [NCBI Gene 653108] {aka CAR, CXADRP}, PBK (PDZ binding kinase) [NCBI Gene 55872] {aka CT84, HEL164, Nori-3, SPK, TOPK}, LOXL2 (lysyl oxidase like 2) [NCBI Gene 4017] {aka LOR, LOR2, WS9-14}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, PTBP1 (polypyrimidine tract binding protein 1) [NCBI Gene 5725] {aka HNRNP-I, HNRNPI, HNRPI, PTB, PTB-1, PTB-T}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, HOTAIR (HOX transcript antisense RNA) [NCBI Gene 100124700] {aka HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072}, FGF23 (fibroblast growth factor 23) [NCBI Gene 8074] {aka ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC}, HCK (HCK proto-oncogene, Src family tyrosine kinase) [NCBI Gene 3055] {aka AIPCV, JTK9, p59Hck, p61Hck}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, IL7 (interleukin 7) [NCBI Gene 3574] {aka IL-7, IMD130}, RB1 (RB transcriptional corepressor 1) [NCBI Gene 5925] {aka OSRC, PPP1R130, RB, p105-Rb, p110-RB1, pRb}, TIGIT (T cell immunoreceptor with Ig and ITIM domains) [NCBI Gene 201633] {aka VSIG9, VSTM3, WUCAM}, IPP (intracisternal A particle-promoted polypeptide) [NCBI Gene 3652] {aka KLHL27}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, FLT4 (fms related receptor tyrosine kinase 4) [NCBI Gene 2324] {aka CHTD7, FLT-4, FLT41, LMPH1A, LMPHM1, PCL}, POU5F1 (POU class 5 homeobox 1) [NCBI Gene 5460] {aka OCT3, OCT4, OCT4Borf1, OTF-3, OTF3, OTF4}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, C1QA (complement C1q A chain) [NCBI Gene 712] {aka C1QD1}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, IL27 (interleukin 27) [NCBI Gene 246778] {aka IL-27, IL-27A, IL27A, IL27p28, IL30, p28}, ALKBH5 (alkB homolog 5, RNA demethylase) [NCBI Gene 54890] {aka ABH5, OFOXD, OFOXD1}, RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198] {aka PS6K, S6K, S6K-beta-1, S6K1, STK14A, p70 S6KA}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, PDS5B (PDS5 cohesin associated factor B) [NCBI Gene 23047] {aka APRIN, AS3, CG008}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, EPOR (erythropoietin receptor) [NCBI Gene 2057] {aka EPO-R}, MCAM (melanoma cell adhesion molecule) [NCBI Gene 4162] {aka CD146, HEMCAM, METCAM, MUC18, MelCAM}, KIF4A (kinesin family member 4A) [NCBI Gene 24137] {aka KIF4, KIF4G1, MRX100, TMDI, XLID100}, CCNE1 (cyclin E1) [NCBI Gene 898] {aka CCNE, pCCNE1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, LINC00266-1 [NCBI Gene 140849], ZMIZ1-AS1 (ZMIZ1 antisense RNA 1) [NCBI Gene 283050], CXCR2 (C-X-C motif chemokine receptor 2) [NCBI Gene 3579] {aka CD182, CDw128b, CMKAR2, IL8R2, IL8RA, IL8RB}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, HOXA@ (homeobox A cluster) [NCBI Gene 3197] {aka HOX1@}, MIR1286 (microRNA 1286) [NCBI Gene 100302118] {aka MIRN1286, hsa-mir-1286, mir-1286}, NECTIN2 (nectin cell adhesion molecule 2) [NCBI Gene 5819] {aka CD112, HVEB, PRR2, PVRL2, PVRR2}, MCL1 (MCL1 apoptosis regulator, BCL2 family member) [NCBI Gene 4170] {aka BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, Mcl-1}, MARCO (macrophage receptor with collagenous structure) [NCBI Gene 8685] {aka SCARA2, SR-A6}, CD276 (CD276 molecule) [NCBI Gene 80381] {aka 4Ig-B7-H3, B7-H3, B7H3, B7RP-2}, SEMA3A (semaphorin 3A) [NCBI Gene 10371] {aka COLL1, HH16, Hsema-I, Hsema-III, SEMA1, SEMAD}, MRC2 (mannose receptor C-type 2) [NCBI Gene 9902] {aka CD280, CLEC13E, ENDO180, UPARAP}, LAG3 (lymphocyte activating 3) [NCBI Gene 3902] {aka CD223}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, TUG1 (taurine up-regulated 1) [NCBI Gene 55000] {aka LINC00080, NCRNA00080, TI-227H}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, CASC2 (cancer susceptibility 2) [NCBI Gene 255082] {aka C10orf5}, CSF3 (colony stimulating factor 3) [NCBI Gene 1440] {aka C17orf33, CSF3OS, GCSF}
- **Diseases:** bone tumor (MESH:D001859), osteoclast (MESH:D001862), bone destruction (MESH:D001847), OS metastasis (MESH:D009362), NLR (MESH:D015467), sarcoma (MESH:D012509), NETs (MESH:C536657), ectopic bone formation (MESH:D000072717), injury to (MESH:D014947), acidosis (MESH:D000138), osteolysis (MESH:D010014), TAMs (MESH:D000072716), tumorigenic (MESH:D002471), cytotoxic (MESH:D064420), Cancer (MESH:D009369), hypoxia (MESH:D000860), Ewing's sarcoma (MESH:D012512), lymphocyte dysfunction (MESH:D015451), inflammation (MESH:D007249), OS (MESH:D012516), TAM (MESH:D020914), metastatic disease (MESH:D000092182), hypoxic (MESH:D002534)
- **Chemicals:** polyamine (MESH:D011073), curcumol (MESH:C022801), regorafenib (MESH:C559147), nitric oxide (MESH:D009569), BioRender (-), bisphosphonate (MESH:D004164), curcumin (MESH:D003474), bezafibrate (MESH:D001629), doxorubicin (MESH:D004317), lipid (MESH:D008055), sodium valproate (MESH:D014635), cisplatin (MESH:D002945), ginsenoside Rg3 (MESH:C097367), V-BAP (MESH:C034853), chitosan (MESH:D048271), methotrexate (MESH:D008727), hydralazine (MESH:D006830), reactive oxygen species (MESH:D017382), BH3 (MESH:C006008), denosumab (MESH:D000069448), vitamin E (MESH:D014810), apatinib (MESH:C553458), DCC-2036 (MESH:C560099), ZOL (MESH:D000077211), calcium silicate (MESH:C031293), medroxyprogesterone acetate (MESH:D017258)
- **Species:** Bos taurus (bovine, species) [taxon 9913], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MNNG — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0439), OS — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_F864), MG63 — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0426), HOS — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_0312)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025241/full.md

---
Source: https://tomesphere.com/paper/PMC13025241